Trial abstract · §3
KISS-PH2-HSDD — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Functional magnetic resonance imaging response to sexual stimuli | A change in limbic activation. The Institute records that a neuroimaging endpoint is not a clinical endpoint | Low |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Kisspeptin-10 from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Well tolerated in controlled infusion studies | — | — | No serious adverse events reported across the published human research programme, which is substantial for a compound in this series |
| Transient flushing | — | — | Reported |
| Headache | — | — | Reported |
Compound Evidence Institute · CEI-TR-0143/3 · https://compoundevidence.com/trials/kiss-ph2-hsdd/results/ · retrieved 30 July 2026